Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy | Zendy

Ali Momeni | Zendy; Mohammad Saeed Behradmanesh | Zendy; Soleiman Kheiri | Zendy; Mohammad Karami Horestani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy

Author(s) -

Ali Momeni,

Mohammad Saeed Behradmanesh,

Soleiman Kheiri,

Mohammad Karami Horestani

Publication year - 2013

Publication title -

journal of the renin-angiotensin-aldosterone system

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.457

H-Index - 46

eISSN - 1752-8976

pISSN - 1470-3203

DOI - 10.1177/1470320313481485

Subject(s) - hydrochlorothiazide , spironolactone , medicine , proteinuria , diabetic nephropathy , aldosterone , endocrinology , urology , diabetes mellitus , kidney , blood pressure

Inhibitors of the renin-angiotensin aldosterone system (RAAS) are the basic drugs for treatment of diabetic nephropathy, as to some extent is spironolactone. The aim of the study was to evaluate the effect of spironolactone versus spironolactone plus hydrochlorothiazide in decreasing proteinuria in type 2 diabetic mellitus (T2DM) patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research